Compass Therapeutics (CMPX) Total Liabilities (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Total Liabilities data on file, last reported at $18.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 11.69% year-over-year to $18.7 million; the trailing twelve-month figure through Mar 2026 stood at $18.7 million (down 11.69% YoY), and the FY2025 full-year result was $22.8 million, up 50.28% from the prior year.
• Total Liabilities declined to $18.7 million in Q1 2026, from $22.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $23.5 million in Q2 2025 to a low of $4.1 million in Q1 2024.
• A 5-year average of $14.4 million and a median of $12.7 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities slumped 67.88% in 2024 and jumped 418.67% in 2025, its largest moves.
• Tracing CMPX's Total Liabilities over 5 years: stood at $18.0 million in 2022, then slumped by 53.7% to $8.3 million in 2023, then jumped by 81.96% to $15.2 million in 2024, then soared by 50.28% to $22.8 million in 2025, then decreased by 17.98% to $18.7 million in 2026.
• Business Quant data shows CMPX's Total Liabilities at $18.7 million in Q1 2026, $22.8 million in Q4 2025, and $21.6 million in Q3 2025.